Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials
A Blauvelt, K Reich, KA Papp, AB Kimball, M Gooderham, SK Tyring, R Sinclair, D Thaci, Q Li, N Cichanowitz, S Green, C La Rosa
British Journal of Dermatology | WILEY | Published : 2018
This research was supported by Merck & Co., Inc., Kenilworth, NJ, U.S.A. Medical writing and editorial assistance were provided by Erin P. Scott, PhD, of Scott Medical Communications, LLC. This assistance was funded by Merck & Co., Inc.